crusia
tzamal bio-pharma ltd - enoxaparin sodium - solution for injection - enoxaparin sodium 100 mg / 1 ml - enoxaparin - crusia is indicated in adults for:•prophylaxis of venous thromboembolic disease in moderate and high risk surgical patients, in particular those undergoing orthopaedic or general surgery including cancer surgery.•prophylaxis of venous thromboembolic disease in medical patients with an acute illness (such as acute heart failure, respiratory insufficiency, severe infections or rheumatic diseases) and reduced mobility at increased risk of venous thromboembolism.•treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), excluding pe ikely to require thrombolytic therapy or surgery. prevention of thrombus formation in extra corporeal circulation during haemodialysis.•acute coronary syndrome:-treatment of unstable angina and non st-segment elevation myocardial infarction (nstemi), in combination with oral acetylsalicylic acid.-treatment of acute st-segment elevation myocardial infarction (stemi) including patients to be managed medically or with subsequent percutaneous coronary intervention (pci).
crusia 2000 iu (20 mg)0.2 ml solution for injection in pre-filled syringe
unimed sdn bhd - enoxaparin sodium -
crusia 4000 iu (40 mg)0.4 ml solution for injection in pre-filled syringe
unimed sdn bhd - enoxaparin sodium -
crusia 6000 iu (60 mg)0.6 ml solution for injection in pre-filled syringe
unimed sdn bhd - enoxaparin sodium -
crusia 8000 iu (80 mg)0.8 ml solution for injection in pre-filled syringe
unimed sdn bhd - enoxaparin sodium -
crusia forte
tzamal bio-pharma ltd - enoxaparin sodium - solution for injection - enoxaparin sodium 150 mg / 1 ml - enoxaparin - crusia is indicated in adults for:•prophylaxis of venous thromboembolic disease in moderate and high risk surgical patients, in particular those undergoing orthopaedic or general surgery including cancer surgery.•prophylaxis of venous thromboembolic disease in medical patients with an acute illness (such as acute heart failure, respiratory insufficiency, severe infections or rheumatic diseases) and reduced mobility at increased risk of venous thromboembolism.•treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), excluding pe ikely to require thrombolytic therapy or surgery. prevention of thrombus formation in extra corporeal circulation during haemodialysis.•acute coronary syndrome:-treatment of unstable angina and non st-segment elevation myocardial infarction (nstemi), in combination with oral acetylsalicylic acid.-treatment of acute st-segment elevation myocardial infarction (stemi) including patients to be managed medically or with subsequent percutaneous coronary intervention (pci).
crusia-aft
aft pharmaceuticals ltd - enoxaparin sodium 100 mg/ml; - solution for injection - 100 mg/ml - active: enoxaparin sodium 100 mg/ml excipient: water for injection - treatment of venous thromboembolic disease.
crusia-aft forte
aft pharmaceuticals ltd - enoxaparin sodium 150 mg/ml; - solution for injection - 150 mg/ml - active: enoxaparin sodium 150 mg/ml excipient: water for injection - treatment of venous thromboembolic disease.
crusia 10.000 ie (100 mg)/1 ml injektionslösung in einer fertigspritze
crusia 12.000 ie (120 mg)/0,8 ml injektionslösung in einer fertigspritze